Treatment of adjuvant arthritis using microencapsulated antisense NF-κB oligonucleotides

Authors: Akhavein, Nima¹; Oettinger, Carl²; Gayakwad, Sanjay¹; Addo, Richard¹; Bejugam, Naveen¹; Bauer, John¹; Do, Duc¹; Pollock, Stanley¹; D'souza, Martin¹

Source: Journal of Microencapsulation, Volume 26, Number 3, May 2009 , pp. 223-234(12)

Publisher: Informa Healthcare

Buy & download fulltext article:

Price: $34.29 plus tax (Refund Policy)

Abstract:

Antisense oligonucleotides are promising new therapeutic agents used to selectively inhibit target genes such as Nuclear Factor Kappa B (NF-κB), an important transcription factor in the pathogenesis of inflammatory disease. The purpose of the present study was to evaluate microencapsulated antisense oligonucleotides specific to NF-κB for in vitro efficacy and treatment of adjuvant-induced arthritis in rats. Oligonucleotide-loaded albumin microspheres were prepared and characterized in terms of size, zeta potential, morphology and release pattern. This study reports significant NF-κB inhibition in vitro after treatment with microencapsulated antisense oligonucleotides. Furthermore, microencapsulated antisense NF-κB oligonucleotides were found to inhibit paw inflammation associated with rat adjuvant-induced arthritis in a dose-dependent manner. Taken together, the results presented in this work described albumin microspheres to be effective delivery vehicles for antisense NF-κB oligonucleotides and a potential treatment for inflammatory diseases.

Keywords: NF-κB; microspheres; albumin; adjuvant arthritis

Document Type: Research article

DOI: http://dx.doi.org/10.1080/02652040802268691

Affiliations: 1: College of Pharmacy and Health Sciences, Mercer University, Atlanta, Georgia, USA 2: Dialysis Clinic, Atlanta, Georgia, USA

Publication date: 2009-05-01

More about this publication?